HBM HOLDINGS-B Shares Surge Over 5% on Positive Preclinical Data for AI-Derived Drug Candidate

Stock News06-04

Shares of HBM HOLDINGS-B (02142) climbed more than 5% in the afternoon session.

As of the latest update, the stock was up 5.01% to HK$10.9, with a turnover of HK$61.25 million.

The move follows the company's recent announcement of promising preclinical data for LET003, its first drug candidate developed using the Hu-mAtrIx™ AI platform.

This next-generation monoclonal antibody targets ACVR2A/2B.

The results indicated that LET003 exhibits superior pharmacokinetic characteristics compared to several competing molecules.

When used in combination with semaglutide, it significantly enhanced fat reduction while effectively preserving lean body mass.

Furthermore, at lower doses, LET003 achieved effects on increasing lean body mass comparable to higher doses of bimagrumab, highlighting its potential to become a best-in-class therapy for obesity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment